Terms: = Breast cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
363 results:
1. EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer.
Li Z; Liu Q; Cai Y; Ye N; He Z; Yao Y; Ding Y; Wang P; Qi C; Zheng L; Wang L; Zhou J; Zhang QQ
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167114. PubMed ID: 38447883
[TBL] [Abstract] [Full Text] [Related]
2. ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin β3-vegfr2 interaction.
Benedetti A; Turco C; Gallo E; Daralioti T; Sacconi A; Pulito C; Donzelli S; Tito C; Dragonetti M; Perracchio L; Blandino G; Fazi F; Fontemaggi G
Cell Death Dis; 2024 Feb; 15(2):113. PubMed ID: 38321003
[TBL] [Abstract] [Full Text] [Related]
3. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a vegfr inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
[TBL] [Abstract] [Full Text] [Related]
4. (E)-2-Methoxy-4-(3-(4-Methoxyphenyl) Prop-1-en-1-yl) Phenol Suppresses breast cancer Progression by Dual-Regulating vegfr2 and PPARγ.
Kim NY; Park HM; Lee HP; Hong JT; Yoon DY
J Microbiol Biotechnol; 2024 Feb; 34(2):240-248. PubMed ID: 37942548
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
6. Antitumor activity of the new tyrphostin briva against BRAF
Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B
Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738
[TBL] [Abstract] [Full Text] [Related]
7. Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, vegfr-2 inhibition, apoptosis induction and migration inhibition studies.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk BA; Husein DZ; Asmaey MA; Ibrahim IM; Metwaly AM
Pathol Res Pract; 2023 Nov; 251():154894. PubMed ID: 37857034
[TBL] [Abstract] [Full Text] [Related]
8. Thymus Vulgaris Oil Nanoemulsion: Synthesis, Characterization, Antimicrobial and Anticancer Activities.
Doghish AS; Shehabeldine AM; El-Mahdy HA; Hassanin MMH; Al-Askar AA; Marey SA; AbdElgawad H; Hashem AH
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836753
[TBL] [Abstract] [Full Text] [Related]
9. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
Tan A; Nong L; Wang H; Jia Y; Zhong W; Qin F; Wang H; Tang J; Liu Y; Lu Y
Cancer Biol Ther; 2023 Dec; 24(1):2265055. PubMed ID: 37831547
[TBL] [Abstract] [Full Text] [Related]
10. Vascular endothelial growth factor antagonist peptides inhibit tumor growth and metastasis in breast cancer through repression of c-src and STAT3 genes.
Bejari M; Sasani ST; Asghari SM; Kolshan MN
Mol Biol Rep; 2023 Nov; 50(11):9213-9219. PubMed ID: 37789224
[TBL] [Abstract] [Full Text] [Related]
11. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract] [Full Text] [Related]
12. N-acylhydrazone derivative modulates cell cycle regulators promoting mitosis arrest and apoptosis in estrogen positive MCF-7 breast cancer cells.
Melo ML; Fonseca R; Pauli F; Zavan B; Hanemann JAC; Miyazawa M; Caixeta ES; Nacif JLM; Aissa AF; Barreiro EJ; Ionta M
Toxicol In Vitro; 2023 Dec; 93():105686. PubMed ID: 37652252
[TBL] [Abstract] [Full Text] [Related]
13. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract] [Full Text] [Related]
14. Expression-Based Diagnosis, treatment Selection, and Drug Development for breast cancer.
Ye Q; Wang J; Ducatman B; Raese RA; Rogers JL; Wan YW; Dong C; Padden L; Pugacheva EN; Qian Y; Guo NL
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445737
[TBL] [Abstract] [Full Text] [Related]
15. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
16. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.
Khaparkhuntikar K; Maji I; Gupta SK; Mahajan S; Aalhate M; Sriram A; Gupta U; Guru SK; Kulkarni P; Singh PK
J Biomol Struct Dyn; 2024; 42(3):1469-1484. PubMed ID: 37272883
[TBL] [Abstract] [Full Text] [Related]
17. Current progress in the targeted therapy of breast cancer: Structure-activity correlation and docking studies (2015-2021).
Pandey S; Mondal S; Kajal K; Kurmi BD; Verma SK; Patel P
Arch Pharm (Weinheim); 2023 Aug; 356(8):e2200602. PubMed ID: 37211680
[TBL] [Abstract] [Full Text] [Related]
18. Evaluating everolimus for the treatment of breast cancer.
Moreau-Bachelard C; Robert M; Gourmelon C; Bourbouloux E; Patsouris A; Frenel JS; Campone M
Expert Opin Pharmacother; 2023; 24(10):1105-1111. PubMed ID: 37183684
[TBL] [Abstract] [Full Text] [Related]
19. P2Y
Jin H; Ko YS; Yun SP; Park SW; Kim HJ
Int J Oncol; 2023 Jun; 62(6):. PubMed ID: 37165911
[TBL] [Abstract] [Full Text] [Related]
20. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and vegfr-2 in the treatment of triple-negative cancer via in silico approach.
Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
[TBL] [Abstract] [Full Text] [Related]
[Next]
